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esponsibility of InstAbstract Indinavir is a protease inhibitor used in the treatment of HIV infection. However, it has limited
efﬁcacy in eradicating the virus in the brain due to efﬂux by P-glycoprotein (P-gp) expressed at the blood–
brain barrier (BBB). The objective of this work was to develop an o/w lipid nanoemulsion (LNE) of
indinavir using Tween 80 as co-emulsiﬁer to improve its brain speciﬁc delivery. LNEs were prepared with
different compositions and were characterized for globule size, polydispersity index, zeta potential and
in vitro drug release. Five formulations were then evaluated for drug content, entrapment efﬁciency and
stability after which brain uptake studies were carried out using ﬂuorescent labeled LNEs and
pharmacokinetic (PK) and tissue distribution studies were conducted after intravenous administration in
mice. Brain uptake of indinavir was shown to be improved for a 1% Tween 80 containing formulation (F5)
compared to a formulation containing 0.3% cholesterol (F2). In PK studies, the brain level of indinavir
subsequent to administration of F5 was signiﬁcantly (Po0.05) higher than produced by administration of a
drug solution (2.44-fold) or a control nanoemulsion (F1) (1.48-fold) or formulation F2 (1.6-fold). The
increased brain speciﬁc accumulation of indinavir from F5 is probably due to enhanced low density
lipoprotein-mediated endocytosis and P-gp inhibition by Tween 80 at the BBB. These results suggest Tween
80 containing LNEs could provide a simple but effective means of delivering indinavir to brain.
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K. Prabhakar et al.3461. Introduction
Infection with the human immunodeﬁciency virus (HIV) often
results in progression to the acquired immune deﬁciency syndrome
(AIDS). The HIV retrovirus is found in the brain soon after
infection and leads to a variety of central nervous system adverse
effects1. HIV in the periphery is signiﬁcantly reduced by highly
active antiretroviral therapy (HAART) comprised of multiple small
molecule therapeutics. However, certain tissues including brain,
macrophages and testis remain reservoirs for HIV infection even
with HAART1,2. This is because the drugs used in HAART have
only limited ability to cross the blood–brain barrier (BBB) into
brain parenchyma.
Among the drugs used to treat HIV infection, indinavir is an
anti-retroviral protease inhibitor used as a part of the HAART
regimen in patients with AIDS. The sub-therapeutic concentration
of indinavir in brain leads to failure of treatment and results in the
development of drug-resistant viral strains in brain despite the
presence of adequate plasma concentrations3. The reason for
the sub-therapeutic concentration in brain is due to efﬂux by
P-glycoprotein (P-gp) expressed at the BBB4–7. Increasing the
brain concentration of indinavir by improving its permeation of the
BBB is therefore a key to reducing the viral burden in brain during
antiretroviral therapy.
Different strategies can be used to improve levels of indinavir in
brain, including co-administration of P-gp inhibitors8 and use of
colloidal carriers9. Among the various colloidal carriers, lipid
nanoemulsions (LNEs) have been used as drug carriers for poorly
aqueous soluble drugs such as indinavir to improve their oral
bioavailability10, sustained release11 and targeting12,13. The LNEs
of indinavir coupled with holo-transferrin14 or pegylation15 or by
incorporation of lipoaminoacids as ligands16 have been reported to
provide brain speciﬁc/targeted delivery of indinavir. Furthermore,
administration of a suspension of a lipid-associated indinavir
complex reduced the HIV viral RNA load in macaques17.
Tween 80 (Polysorbate 80, polyoxyethylene sorbitan mono-
oleate) is a hydrophilic nonionic surfactant widely used in
emulsiﬁcation and dispersion of substances in medicinal and food
products18,19. Not only it is useful as an emulsifying agent in
emulsions20 and multiple emulsions21,22, and as a co-emulsifying
agent for reducing the globule size in lipid emulsions23, but also
has the advantage in relation to indinavir of being an inhibitor of
intestinal P-gp. Thus it has been used to increase the permeabilityTable 1 Composition of lipid nanoemulsions of indinavir.
Formulation ingredient (% w/v) No cholesterol Cholestero
F1 F2
Indinavir 0.1 0.1
Soya bean oil 10 10
Egg lecithin 1.2 1.2
Cholesterol 0 0.3
α-Tocopherol acetate 0.25 0.25
Oleic acid 0.3 0.3
Tween 80 0 0
Glycerol 2.25 2.25
Did oil (Dil C18) – –
Doubly distilled water (mL) 10 10
nFluorescent dye (DiD oil) containing LNEs.of numerous drugs in rats in vivo24, in Caco-2 cells in vitro25, in
tissues such as rat intestinal membrane ex vivo26 and in the
inverted rat intestinal sac27. In addition, it has been used in
conjunction with nanoparticles to improve brain speciﬁc delivery
of several drugs including tacrine28, doxorubicin29, the hexapep-
tide dalargin30, loperamide31 and tubocurarine32, by increasing
LDL-mediated endocytosis.
The objective of this work was to develop indinavir LNEs using
lecithin as emulsiﬁer and Tween 80 as co-emulsiﬁer. The effect of
Tween 80 containing LNEs on brain delivery of indinavir was
investigated in mice by determining plasma and tissue levels of
drug after intravenous administration. The therapeutic availability
and targeting potential were calculated to evaluate the efﬁcacy of
Tween 80 containing formulations in comparison to drug solution
and control LNEs.2. Materials and methods
2.1. Materials
Indinavir was generously provided by Matrix Laboratories (Hyder-
abad, India). Egg phosphatidyl choline and EPC-80 were gifts from
Lipoid (Germany). Reﬁned soyabean oil was obtained from Fluka
(Mumbai, India). Tween 80, cholesterol, glycerol, methanol and
acetonitrile were products of Merck (Mumbai, India). DiD oil (1,1′-
dioctadecyl-3,3,3′,3′-tetramethyl-indocarbocyanine perchlorate), α-
tocopherol, triethylamine and phosphoric acid were purchased from
Sigma (Mumbai, India). Sodium dihydrogen phosphate, disodium
hydrogen phosphate, sodium chloride and oleic acid were from S.D.
Fine Chemicals (Mumbai, India). Centrisart tubes and dialysis mem-
branes were products of Sartorius (Germany) and HiMedia (Mumbai,
India), respectively. All other chemicals were of reagent grade and
used as received.
2.2. Preparation of LNEs
LNEs were prepared with the compositions shown in Table 1 using
a hot homogenization and ultrasonication process. The formula
consisted of 10% w/v soybean oil as the oil core, 1.2% w/v EPC-80
as a phospholipid emulsiﬁer, oleic acid (0.3% w/v) as a negative
charge inducer, α-tocopherol (0.25% w/v) as antioxidant and
glycerol (2.25% w/v) to maintain isotonicity for intravenousl (0.3%) Tween 80
*F2 F3 F4 F5 *F5
0.1 0.1 0.1 0.1 0.1
10 10 10 10 10
1.2 1.2 1.2 1.2 1.2
0.3 0.3 0.3 0.3 0.3
0.25 0.25 0.25 0.25 0.25
0.3 0.3 0.3 0.3 0.3
0 0.2 0.6 1.0 1.0
2.25 2.25 2.25 2.25 2.25
0.1 – – – 0.1
10 10 10 10 10
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(oil phase) and water soluble substances to the aqueous phase. Both
phases were then heated to 70 1C after which the aqueous phase
was added to the oil phase with stirring and the mixture homo-
genized for about 3 min at 15,000 rpm (Homogenizer Diax 900,
Heidolph, Germany). Finally, the mixture was sonicated (750 W,
Vibra Sonics, Sonics and Materials Inc., USA) for about 20 min at
50% amplitude. LNEs were prepared using 0.2%, 0.6% and 1% w/v
Tween 80 keeping the other ingredients constant.
2.3. Determination of globule size (GS) and polydispersity index
(PDI)
LNEs diluted 1:100 with doubly distilled water were put in a
cuvette and placed inside the sample holder of a Malvern Nano
ZS90 zeta sizer (Malvern, UK) for measurement of GS and PDI.
The observations for GS determination were recorded at a light
scattering angle of 901 and a temperature of 25 1C. The photon
correlation spectroscopic principle was used to determine the
hydrodynamic diameter of globules via Brownian motion.
2.4. Determination of zeta potential (ZP)
LNEs diluted 1:100 with doubly distilled water were placed in a
disposable cuvette and inserted into the sample holder of the
Malvern Nano ZS90 zeta sizer. The ZP value was measured by the
built-in software which uses the Helmholtz–Smoluchowski equa-
tion describing the electrophoretic mobility of globules.
2.5. In vitro drug release
Dialysis through cellulose membranes (DM 60, molecular weight
cut-off 12000, Himedia, Mumbai, India) was used to study in vitro
drug release based on a reported method8 with slight modiﬁcation.
A 100 mL mixture of 30% ethanol and phosphate buffer pH 7.4 in
a 250 mL beaker was used as dialysis medium. The amount of
drug in samples collected over 12 h was determined by UV
absorption at 215 nm using an ELICO SL 159 UV–vis spectro-
photometer (Hyderabad, India). Cumulative percentage drug
release vs. time was plotted to evaluate the release pattern of drug
from a drug solution and the different formulations.
2.6. Determination of drug content and entrapment efﬁciency
(EE)
Indinavir in LNEs and aqueous media was determined by reversed
phase HPLC8 using an LC-10AT VP solvent delivery system
(Shimadzu, Kyoto, Japan), an SPD-10 A VP variable wavelength
detector (Shimadzu) set at 215 nm, a Lichrosphers C18 analytical
column (250 nm 4.6 mm, 5 μm) (Merck, Mumbai, India) at
ambient temperature and an injector ﬁtted with a 20 mL loop.
The mobile phase consisted of 68% phosphoric acid solution
adjusted to pH 5.5 with triethylamine and 32% acetonitrile
delivered at a ﬂow rate of 1 mL/min. Sample preparation and
assay validation is described in Section 2.9.2. Drug content of
indinavir loaded LNEs (0.5 mL) was determined by ﬁrst diluting
samples with 10 mL chloroform/methanol mixture (1:1) and
making a ﬁnal dilution in mobile phase. EE was determined by
measuring the concentration of free drug in the aqueous medium
after ultraﬁltration33 through the ﬁlter membrane (molecular
weight cut off 20 k Da) of Centrisart tubes at the base of thesample receiver chamber. About 2 mL of a formulation was placed
in the donor chamber and centrifuged at 6500 rpm for 15 min
(C24, Remi instruments Ltd., Mumbai, India).
2.7. Stability studies
Stability of optimized LNEs was evaluated for the effects of
centrifugal, thermal and dilution stress and on storage at 4 and
25 1C for 6 months. Centrifugal stress involved taking 1 mL
aliquots of LNEs in 1.5 mL Eppendorf tubes and centrifuging
(Heraeus Biofuge, Germany) at 13,000 rpm for 10 min. The
creaming volume percentage for each LNE was calculated as
previously described34 and the formulations compared. Thermal
stress involved subjecting LNEs to autoclaving at 121 1C for
15 min and then determining any changes in GS, PDI and ZP.
Dilution stress involved diluting LNEs with doubly-distilled water
in ratios of 1:50, 1:100, 1:200, 1:500, 1:1000 and 1:5000 and
evaluating GS and ZP. Stability on storage was investigated by
taking samples (1 mL) into 2 mL Eppendorf tubes after 1 day and
after 1, 2, 3, 4 and 6 months and measuring GS, PDI and ZP.
2.8. Brain uptake studies by ﬂuorescence microscopy
Male Swiss-albino mice (Mahaveera Enterprises, Hyderabad,
India) weighing 24–26 g were used in the study. The animals
were kept in cages and provided with water and standard diet
(NIN, Hyderabad) ad libitum. After animals were acclimatized to
the environmental conditions, they received single 5 mg/kg doses
of formulations nF2 or nF5 containing a ﬂuorescent dye (DiD oil)
by tail vein injection. After 0.25 h, animals were anaesthetized,
decapitated and the whole brains removed and frozen at 80 1C.
Frozen brains were immediately treated with tissue freezing
medium (Leica) and 5 mm microsections prepared using a cryo-
microtome (Cryostat, Leica CM 3050 S). The microsections were
mounted on glass slides and covered with aluminum foil to prevent
the loss of ﬂuorescence due to light. The microsections were
photographed using a ﬂuorescent microscope (Nikon E 800,
Nikon, Japan) with excitation and emission wavelengths of 520
and 540 nm, respectively.
2.9. Pharmacokinetic (PK) and tissue distribution studies
These studies were performed using protocols, procedures and
methods reported earlier14 and brieﬂy described below.
2.9.1. Animals and sample collection
The protocol for the animal experiments was reviewed and approved
by Animal Ethical Committee of our institution. A total of 72 male
Swiss-albino mice (weight 24–26 g) were randomly divided into
four groups (n¼18 per group) and kept in cages provided with
water and standard diet (NIN, Hyderabad) ad libitum. Before the
day of an experiment, mice were fasted overnight with water
provided ad libitum. On the day of an experiment, groups of mice
were anaesthetized with ether and given a single intravenous (tail
vein) injection of either indinavir or an indinavir formulation (F1, F2
or F3; 5 mg/kg indinavir) dissolved in a saline-propylene glycol-
ethanol vehicle (5:4:1, v/v/v; 1 mg/mL).. The animals were kept
unrestrained during the entire study. At 0.25, 0.5, 1, 2, 4 and 6 h
after the dose, animals were anesthetized with ether and a blood
sample withdrawn from the retro-orbital sinus vein into a hepar-
inized polypropylene tube. Animals were then decapitated and tissue
Table 2 Effect of concentration of Tween 80 on globule size, PDI and zeta potentials of formulations (n¼3).
Formulation Variable ingredient (% w/v) Size (nm) PDI Zp (mV)
F1 No cholesterol 329.573.08 0.07970.05 35.876.04
F2 Tween 80 (0) 237.075.08 0.24570.01 31.371.80
F3 Tween 80 (0.2) 226.072.00 0.14570.03 37.371.20
F4 Tween 80 (0.6) 208.573.50 0.10770.09 38.573.50
F5 Tween 80 (1) 196.073.54 0.06870.03 40.174.02
K. Prabhakar et al.348samples (whole brain, lungs, heart, liver, kidney and spleen) were
collected. Plasma was separated by centrifuging blood at
13,000 rpm for 10 min and tissue samples were washed with normal
saline. All samples were frozen at 80 1C until drug analysis.
2.9.2. Determination of drug in biological samples
The reversed-phase HPLC method described in Section 2.6 was
slightly modiﬁed and used for the determination of indinavir
concentration in biological samples. All solutions were prepared in
water:acetonitrile (50:50 v/v). Stock solutions (1 mg/mL) of indi-
navir were prepared and diluted to give standard solutions of
concentration 0.1, 0.25, 0.5, 1, 2.5 and 5 mg/mL. A stock solution
(1 mg/mL) of verapamil hydrochloride as internal standard (IS)
was diluted to give a working 5 mg/mL IS solution. To 500 mL
tissue homogenate (either sample or control obtained from drug
free animals) prepared in ice cold saline [0.2 g tissue per mL
prepared using a tissue homogenizer (Remi Instruments Ltd.,
Mumbai, India) at 6000 rpm], 100 mL perchloric acid (60%) was
added and, after vortex-mixing for 5 min, the resulting suspension
was centrifuged at 13,000 rpm for 10 min (Biofuge, Heraeus,
Germany). To 300 mL plasma or tissue homogenate supernatant,
100 mL standard indinavir solution, 100 mL IS working solution,
1 mL 4 M KOH solution and 5 mL diethyl ether were added
and the resulting mixture vortexed for 15 min and then cen-
trifuged at 6500 rpm for 10 min. The organic layer was separated
and evaporated to dryness under vacuum (GL 66, Toshniwal,
Mumbai, India) after which the residue was reconstituted in
100 mL 100 mM phosphoric acid and 20 mL of the resulting
solution was injected to HPLC. Linear regression of calibra-
tion curves gave with the following equations and correla-
tion coefﬁcients: Plasma Y¼0.263Xþ0.001, R2¼0.998; brain
Y¼0.172Xþ0.001, R2¼0.997; lung Y¼0.208Xþ0.026,
R2¼0.992; heart Y¼0.220Xþ0.017, R2¼0.990; liver
Y¼0.281Xþ0.003, R2¼0.996; kidney Y¼0.258Xþ0.009,
R2¼0.996; and spleen Y¼0.204Xþ0.008, R2¼0.996.
2.9.3. Pharmacokinetic parameters and statistical analysis
Pharmacokinetic parameters (Cmax, Tmax, AUC0–6h, t1/2, MRT) and
therapeutic availability (TA) were calculated using Kinetica soft-
ware (version 5.0) and are expressed as mean7standard deviation
(SD). Comparison between groups was done using the paired
students t-test with Po0.05 considered statistically signiﬁcant.
2.10. Determination of targeting potential
Tissue-to-serum ratios of drug after administration in different
formulations and at different times after dosing were calculated
to determine the targeting potential of the formulation to brain.A ratio greater than 1 indicates good brain targeting of the
formulation.3. Results
3.1. Characterization of LNEs
GS, PDI and ZP of LNEs are shown in Table 2. As the Tween 80
concentration increased, there was a slight reduction in GS with no
appreciable increase in ZP values. In terms of the in vitro drug
release proﬁles over 12 h, there was no signiﬁcant difference in
cumulative drug release from LNEs F2–F5 with all formulations
giving better release than F1 and drug solution (Fig. 1). Overall,
formulation F5 had lower GS, relatively better release and higher
ZP than the other formulations and was used in further studies.
3.2. Total drug content and EE
The total drug content of formulations F1, F2 and F5 was
10.0170.09, 9.8570.14 and 9.8070.11 mg/mL respectively with
corresponding EE values of 99.070.15, 98.870.03, and
98.970.2, respectively.
3.3. Stability studies
Centrifugal stress is a rapid way to check the stability of LNEs.
The percentage creaming values of F1, F2 and F5 were 96.071.0,
97.870.3 and 99.070.5 and there was no appreciable change in
GS, PDI and ZP of the selected formulations upon autoclaving
(thermal stress) (Fig. 2) or dilution (Table 3). In terms of stability
on storage, GS increased by 10%–25% but ZP remained fairly
constant over the 6 months. On this basis, the LNEs were
physically stable at 4 1C and room temperature for 6 months.
3.4. Brain uptake studies by ﬂuorescence microscopy
Fluorescent images taken 0.25 h after injection of ﬂuorescent dye
(DiD oil, Dil C18) incorporated LNEs via the tail vein indicate that
formulation F5 gives more intense ﬂuorescence of brain tissue than
F2 (Fig. 3), indicating greater brain uptake of this emulsion.
3.5. PK and tissue distribution studies
Plasma levels of drug after adminstration of drug solution were
higher than those after formulations F1, F2 and F5 at 0.25 h
(Fig. 4) but were not signiﬁcantly different at other time points. In
tissue distribution studies, the brain level of indinavir (Fig. 5) from
F5 was higher than that produced by drug solution. F1 and F2
Figure 1 Cumulative percentage indinavir release from drug solution
and formulations F1, F2, F3, F4 and F5 (n¼3) as determined by
equilibrium dialysis.
Figure 2 Effect of autoclaving on GS, PDI and ZP of formulations
F1, F2 and F5 (n¼3).
Table 3 Effect of dilution on globule size, PDI and zeta potentials
Formulation Dilution factor Size (nm
F1 1:50 340.873
1:100 351.072
1:200 358.775
1:500 365.777
1:1000 366.171
1:5000 379.171
F2 1:50 256.375
1:100 263.571
1:200 265.578
1:500 262.475
1:1000 269.273
1:5000 272.571
F5 1:50 200.173
1:100 202.475
1:200 216.075
1:500 233.874
1:1000 245.875
1:5000 257.573
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points but there was no signiﬁcant difference between levels
produced by drug solution, F1 and F2 at different time points.
The AUC0–6h and therapeutic availability (TA) of indinavir are pre-
sented in Table 4 (other parameters are not shown). The AUC0–6h of
indinavir for drug solution14 was higher in plasma than for
formulations F1, F214 or F5 whereas the indinavir level in brain
tissue for F5 was higher than for drug solution or formulations F1
and F2. The TA of drug for F5 in brain tissue was 2.44-fold than for
drug solution, 1.48-fold that for F1 and 1.6-fold that for F2. In other
tissues (lung, liver, kidney and spleen), TA waso1 except in heart
where TA was 41 for F5 and drug solution but not for F1 or F2.
The brain-to-plasma ratio for F5 was higher (1–3-fold) than for
all other formulations at all-time points (Fig. 6). Although the ratio
was o1, F5 delivered indinavir to brain better than the other
formulations.4. Discussion
4.1. Preparation and characterization of LNEs
The content of EPC-80 of 1.2% w/v used in the preparation of
LNEs is reportedly the minimum required for preparation of lipid
emulsions35. Phospholipids are weak emulsiﬁers36 such that the
incorporation of cholesterol into the formulation is required to
enhance rigidity at the interface, produce a more stable formula-
tion37 and retard drug release. In this study, the incorporation of
cholesterol resulted in a decrease in GS but no appreciable change
in ZP (results not shown). Incorporation of different concentrations
of Tween 80 also resulted in a decrease in GS but little change in
ZP possibly due to the non-ionic nature of Tween 80.
4.2. In vitro drug release
There was no difference in cumulative release of drug from formula-
tions F2–F5 which was slower than from drug solution and F1. LNEs
prepared with Tween 80 are smaller in GS and therefore have greaterof optimized formulations (n¼3).
) PDI Zp (mV)
.8 0.0870.04 31.0770.54
.5 0.1070.01 29.8171.35
.9 0.2170.06 27.5070.56
.4 0.2670.10 27.9372.60
2.3 0.2570.04 27.4375.39
3.5 0.2970.05 26.2372.42
.2 0.0770.20 33.7072.91
.6 0.1770.20 31.3070.43
.9 0.2570.41 30.5372.62
.2 0.2970.12 29.4672.41
.7 0.3070.04 28.5071.53
.7 0.2970.10 27.1073.34
.2 0.0570.04 34.0073.51
.0 0.1070.11 33.8072.26
.4 0.1570.05 30.1072.21
.5 0.1970.05 29.0073.52
.6 0.2570.06 28.2073.84
.0 0.1570.13 26.4070.19
Figure 3 Fluorescent images (400 ) of mice brain 0.25 h after intravenous injection of DiD oil incorporated formulations F2 and F5 in
comparison to blank brain tissue.
Figure 4 Plasma proﬁles of indinavir from drug solution and
formulations F1, F2 and F5 after intravenous administration in mice
(n¼3).
Figure 5 Brain proﬁles of indinavir after intravenous adminstration
of indinavir solution and formulations F1, F2 and F5 in mice (n¼3).
K. Prabhakar et al.350surface area for drug release. Furthermore, the hydrophilicity at the
surface of globules is also increased. However, these two properties did
not greatly affect the cumulative release of drug at 12 h. The decrease
in GS produced by 1% Tween 80 concentration was optimal and this
formulation was selected for further study.4.3. Stability studies
It has been reported that emulsions with higher creaming values
have better stability to centrifugal stress34. In this study, all the
optimized formulations showed higher creaming values indicatingthe stability of the LNEs (data not shown). In terms of thermal
stress to which LNEs for intravenous use would be subjected to
ensure sterility, there were no considerable changes in GS or ZP
values on autoclaving indicating the stability of LNEs F1, F2 and
F5. Such stability of phospholipid emulsions after sterilization has
also been reported elsewhere38. In relation to dilution stress,
dilution of an emulsion disturbs the rigidity of the surfactant
layers at the interface leading to changes in ZP39. In this study,
there were no signiﬁcant differences in GS and ZP between the
tested formulations, indicating all the emulsions were stable.
In terms of physical stability of LNEs during storage, there were no
appreciable changes in GS, ZP or PDI, indicating that the LNEs were
stable on storage at 4 1C and room temperature for up to 6 months.
4.4. Fluorescent dye studies
Formulation F5 (Fig. 3) showed more intense ﬂuorescence in brain
than formulation F2 possibly due to a cooperative effect between
cholesterol and Tween 80 at the interface of the emulsion globules
leading to preferential adsorption of apolipoprotein E (Apo-E) and/
or apolipoprotein B (Apo-B) onto the globule surface. Presumably
these modiﬁed globules mimic LDL particles and are transported
into brain by LDL receptor mediated endocytosis9.
4.5. PK and tissue distribution
In the PK study, the higher drug levels in plasma after adminis-
tration of formulation F5 compared to F2 may be due to the greater
hydrophilicity of globules caused by the presence of Tween 80.
Formulation F2 produced lower levels of drug in plasma than F1
and drug solution which could be due to the cholesterol in F2
causing preferential adsorption of Apo-E onto the surface of
globules allowing them to mimic LDL particles and undergo rapid
uptake by organs of the reticulo-endothelial system (RES)40
leading to lower drug levels in plasma.
In brain tissue, formulations F1 and F2 produced higher
indinavir levels (Po0.05) than drug solution. There are several
possible reasons for this increased uptake as proposed by Kreuter41
for entry of nanoparticles into brain. Solid lipid nanoparticles
(SLNs) and LNEs differ only in their physical state (SLNs contain
solid lipid; LNEs contain liquid lipid) and possess similar surface
properties for the same emulsiﬁer. However, LNEs may have the
advantage of superior ﬂexibility allowing them to squeeze through
the endothelial lining. Just like SLNs, LNEs can enter the brain by
absorption of LNE globules onto brain capillary walls leading to
increased retention of LNE globules in brain capillaries and
Table 4 AUC0–6h and therapeutic availability (TA) of optimized LNE formulations.
Sample Parameter Formulation
Dug solutiona F1 F2a F5
Plasma AUC0–6h (mg h/mL) 13.0970.57 14.0472.91 10.6970.55 11.7471.85
TA 1.00 1.07b 0.82b/0.76c 0.89b/0.83c/1.09d
Brain AUC0–6h (mg h/mL) 2.6570.57 4.3671.23
‡ 4.0471.35‡ 6.4871.11‡,†,¶
TA 1.00 1.64b 1.52b/0.92c 2.44b/1.48c/1.6d
Lungs AUC0–6h (mg h/mL) 6.8270.59 3.8570.64 4.3670.35 4.7671.30
TA 1.00 0.56b 0.64b/1.13c 0.69b/1.24c/1.09d
Heart AUC0–6h (mg h/mL) 12.5771.53 7.771.10 8.8870.42 10.0473.88
TA 1.00 0.61b 0.71b/1.15c 0.8b/1.30c/1.13d
Liver AUC0–6h (mg h/mL) 6.4971.66 4.6370.09 4.9771.70 5.272.07
TA 1.00 0.71b 0.76b/1.07c 0.8b/1.12c/1.04d
Kidney AUC0–6h (mg h/mL) 9.1570.48 8.4872.24 6.7571.04 5.7671.42
TA 1.00 0.93b 0.74b/0.79c 0.63b/0.67c/0.85d
Spleen AUC0–6h (mg h/mL) 6.672.07 7.6970.97 6.9470.74 6.1271.55
TA 1.00 1.17b 1.05b/0.90c 0.93b/0.8c/0.88d
aData of drug solution and F2 are from reference 30.
bIndicates TA in comparison to drug solution.
cIndicates TA in comparison to F1.
dIndicates TA in comparison to F2.
‡Statistically signiﬁcant in comparison to drug solution (Po0.05).
†Statistically signiﬁcant in comparison to control emulsion (Po0.05).
¶Statistically signiﬁcant in comparison to cholesterol emulsion (Po0.05).
Figure 6 Brain-to-plasma ratios of indinavir after intravenous
administration of drug solution and formulations F1, F2 and F5 in
mice (n¼3).
Tween 80 containing lipid nanoemulsions for delivery of indinavir to brain 351creating a higher concentration gradient across endothelial cells42.
Endocytosis and transcytosis may also be possible mechanisms for
entry of LNEs into brain because of their lipophilic nature.
The indinavir concentration in brain was increased signiﬁcantly
(Po0.05) for LNEs containing Tween 80 in comparison with drug
solution, F1 and F2. Kreuter43 proposed a mechanism for entry of
Tween 80 containing nanoparticles into brain. The reason for the
increased uptake of LNEs containing Tween 80 across the BBB is
most likely endocytosis via the LDL receptor by endothelial cells
lining brain capillaries. This endocytosis is mediated by the
adsorption of Apo-B and/or Apo-E onto globules from the blood.
The LNEs can then mimic the lipoprotein and the drug may either
be released within these endothelial cells followed by passivediffusion into the brain or be transported into the brain by
transcytosis. Furthermore, Tween 80 has the ability to inhibit
intestinal P-gp and has been used to increase the permeability of
numerous drugs in models of the intestinal wall. Inhibition of P-gp
at the BBB may be another mechanism by which Tween 80
containing LNEs improve brain levels of indinavir.
In other tissues such as lung, liver, heart and kidney, the TA values
of drug solution were greater than that for F1, F2 and F5 but in spleen
the TA value was slightly greater than 1 for F1 and F2 formulations.
In heart the TA for F5 was41 compared to F1 and F2 possibly due
to high levels of lipoprotein lipase present in heart which may induce
lipolysis of LNE globules and result in the higher levels of indinavir
observed. The observation that the TAs of F5, F2 and F1 in kidney
were o1 may suggest LNEs of indinavir will produce less nephro-
lithiasis and crystalluria, common side effects of indinavir.
The brain-to-plasma ratio of F5 was much higher (1–3-fold) than
for all other formulations indicating preferential accumulation of
indinavir in brain for Tween 80 containing LNEs (Fig. 6). F2
exhibited higher brain:plasma ratios than drug solution which could
be due to LDL mediated endocytosis. However, Tween 80 as co-
emulsiﬁer in F5 improved the drug level of indinavir in brain in
comparison to drug solution and formulations F1 and F2. Together
with the results of our previous studies14,15, it can be concluded that
transferrin, PEG 2000, PEG 5000, stearyl amine and Tween 80 can
be used to prepare LNEs with improved brain speciﬁc delivery.5. Conclusions
Stable lipid nanoemulsions containing Tween 80 were prepared,
characterized and evaluated for improving the brain speciﬁc
K. Prabhakar et al.352delivery of indinavir. Fluorescent microscopy and pharmacokinetic
studies in mice clearly demonstrated improved uptake of LNEs by
brain tissue in comparison to control formulations. In fact, Tween
80 containing LNEs increased the brain speciﬁc delivery of
indinavir and may prove to be useful in reducing the viral load
in brain in chronic HIV infection.
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